Clinical trials: Non Alcoholic Fatty Liver
Non Alcoholic Fatty Liver Disease, Type2 Diabetes Mellitus
Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
This D-LIFT (Effect of dulaglutide on Liver Fat) trial is an investigator initiated, prospective, open label, randomized clinical study to examine the effect of dulaglutide 0.75 mg subcutaneously weekly for 4 weeks, followed by…
- Trial name
- D-LIFT (NCT03590626)
- Testing
- Dulaglutide
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Medanta, The Medicity, India
Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus (T2DM)
A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects
The Sponsor is developing the test medicine, cotadutide, for the potential treatment of non-alcoholic steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) with chronic kidney disease.
- Conditions
- Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease
- Trial name
- NCT05294458
- Testing
- cotadutide solution for injection
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects
This study will evaluate safety, tolerability, and Pharmacokinetics (PK) of ID119031166M with the Exploration of Pharmacodynamic (PD) effects in Healthy Participants.
- Trial name
- NCT05604287
- Testing
- ID119031166M
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
Non-Alcoholic Fatty Liver Disease
Combining MRI Steatosis Assessment and Transient Elastography to Improve Liver Fibrosis Diagnosis in Non Alcoholic Fatty Liver Disease
The main objective is to compare the accuracy of transient elastography taking into account liver steatosis determined by MRI, to liver biopsy for the diagnosis of liver fibrosis ≥F2 in patient with NAFLD.
- Trial name
- FibroMR (NCT03245606)
- Testing
- Liver biopsy, Abdominal MRI, Transient elastography
- Where
- 9 sites in France
- Volunteers
- 270 people
- Sponsor
- Rennes University Hospital
NAFLD, Obesity
Influence of a Mediterranean Diet Combined With a Physical Activity Intervention, on NAFLD and Inflammation Parameters.
The study in question is an interventional study with nutritional intervention. The aim of the study is to evaluate whether the adoption of two different models of Mediterranean Diet, based on the different percentage of…
- Conditions
- NAFLD, Obesity, IBS
- Trial name
- NAFLD-POS5 (NCT06275906)
- Testing
- Mediterranean diet and moderate intensity physical exercise (outdoor walking).
- Where
- Italy
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Liver Disease
NAFLD Pediatric Database 2
The NAFLD Database 2 will recruit at least 650 new pediatric participants with liver biopsies and contemporaneous biosamples, and will also invite pediatric participants from the prior NAFLD Database and TONIC trial (50 with a…
- Trial name
- NAFLD Peds DB2 (NCT01061684)
- Where
- 12 sites in United States
- Volunteers
- 969 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Nonalcoholic Fatty Liver Disease
Dietary Treatment Study of Pediatric NAFLD
This is an investigator initiated study being conducted in equal numbers at two sites, University of California, San Diego (UC San Diego) and Emory University (EU).
- Trial name
- DTS (NCT02513121)
- Testing
- Dietary modification
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Diego
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic…
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
- Trial name
- NCT05067621
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Yale University
Nonalcoholic Steatohepatitis
Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis
The purpose of the study is to see if the drug colesevelam is a potential treatment for Nonalcoholic Steatohepatitis(NASH).
- Trial name
- NCT01066364
- Testing
- Colesevelam Hcl
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of California, San Diego
Non-Alcoholic Fatty Liver Disease, Type2diabetes
Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD
This clinical trial will yield results about the therapeutic effect of combining pioglitazone with SGLT2i in people suffering from NAFLD associated with T2DM.
- Trial name
- NCT05942963
- Testing
- Empagliflozin 10 MG, Pioglitazone 15mg, Metformin
- Where
- Pakistan
- Volunteers
- 240 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)
This study is to evaluate the predictive value of NRL972 pharmacokinetics in the diagnosis of steatohepatitis using fatty liver disease as the comparator group.
- Trial name
- NCT00794716
- Testing
- NRL972
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Norgine
Liver Diseases, Alcoholic, Fibrosis
Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
Prospective screening study at Odense University Hospital to assess the effect of transient elastography and other serum and imaging markers of liver fibrosis to detect advanced fibrosis (Kleiner Fibrosis score F3-F4) in patients…
- Trial name
- SIPHON (NCT03308916)
- Testing
- transient elastography, Enhanced liver fibrosis test, Indirect serum markers of liver fibrosis
- Where
- Denmark
- Volunteers
- 6,500 people
- Sponsor
- Maja Thiele
Nonalcoholic Steatohepatitis
First-in-Human Study of SRT-015 in Healthy Subjects.
This is phase 1 first-in-human trial evaluating SRT-015 to assess safety, tolerability and pharmacokinetics. This study will be conducted in 3 parts - SAD, MAD and Food Effect with target of 96 healthy volunteers.
- Trial name
- NCT04887038
- Testing
- SRT-015
- Where
- Australia
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Syneos Health
Non Alcoholic Fatty Liver Disease
Comparison of Effectiveness of Obeticholic Acid With Vitamin E in Patients of Non-alcoholic Fatty Liver Disease
This study was conducted on patients presenting to Mayo Hospital, Lahore from 24th August, 2023 till 23rd May, 2024. Ninety patients conforming to the inclusion criteria were selected via simple random sampling technique and…
- Trial name
- NCT07104786
- Testing
- Obeticholic Acid 10 MG, Vitamin E 400mg
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- King Edward Medical University
Obesity, NAFLD
Study of NGM395 in Adult Participants
Study of NGM395 in adult participants.
- Trial name
- NCT04187339
- Testing
- NGM395
- Where
- Australia
- Volunteers
- 38 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Obesity, Diabetes
Role of Dietary Fatty Acids in Fatty Liver and Insulin Resistance
The purpose of this study is to investigate whether substituting saturated fats with polyunsaturated fats reduces fatty liver and improves insulin action and other metabolic variables in abdominally obese subjects
- Conditions
- Obesity, Diabetes, Insulin Resistance, Fatty Liver
- Trial name
- HEPFAT (NCT01038102)
- Testing
- PUFA Diet, SFA diet
- Where
- Sweden
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Nonalcoholic Steatohepatitis
Non Alcoholic Fatty Liver Disease and Coronary Heart Disease in Type 2 Diabetes Patients
To assess the feasibility in diabetics in a primary care setting of screening for NAFLD and advanced fibrosis, by using non-invasive magnetic resonance imaging (MRI) to estimate the hepatic proton density fat fraction (MRI-PDFF)…
- Trial name
- NCT04462081
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Diego
Non-Alcoholic Fatty Liver Disease, Chronic Kidney Diseases
NAFLD Among Patients With Type 2 Diabetes and CKD
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries affecting approximately 30 % of the general adult population.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Chronic Kidney Diseases, Type2 Diabetes
- Trial name
- NCT03826381
- Testing
- Magnetic resonance (MR) spectroscopy of the liver, Fibroscan, Continuous glucose monitoring (CGM) for four days.
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
NAFLD, NAFLD-HIV
Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure.
- Conditions
- NAFLD, NAFLD-HIV, Hiv
- Trial name
- NCT04795219
- Where
- 8 sites in United States
- Volunteers
- 1,250 people
- Sponsor
- University of California, San Francisco
NAFLD, Obesity, Adolescent
Impact of Weight Loss Surgery in Adolescents With NAFLD
This study will assess the impact of weight loss surgery (WLS) on non-alcoholic fatty liver disease (NAFLD) in adolescents as well as the interaction between NAFLD and cardiometabolic risk.
- Trial name
- AWLS (NCT02952170)
- Testing
- MRI
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.